Mass balance and metabolite profiling of
14C-radiolabeled
Guadecitabine
Mass balance
Metabolite
Pharmacokinetics
ß-decitabine
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
25
06
2019
accepted:
09
09
2019
pubmed:
13
10
2019
medline:
10
9
2021
entrez:
13
10
2019
Statut:
ppublish
Résumé
Purpose The objective of this mass balance trial was to determine the excretory pathways and metabolic profile of the novel anticancer agent guadecitabine in humans after administration of a
Identifiants
pubmed: 31605293
doi: 10.1007/s10637-019-00854-9
pii: 10.1007/s10637-019-00854-9
pmc: PMC7340650
doi:
Substances chimiques
Antineoplastic Agents
0
Carbon Radioisotopes
0
guadecitabine
2KT4YN1DP7
Azacitidine
M801H13NRU
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1085-1095Références
Cancer Res. 1986 Sep;46(9):4831-6
pubmed: 2425959
J Phys Chem B. 2013 Nov 27;117(47):14599-614
pubmed: 24134404
J Pharm Biomed Anal. 2019 Feb 5;164:16-26
pubmed: 30366147
Drugs Future. 2013 Aug;38(8):535-543
pubmed: 26190889
Pharmacol Res. 2007 Jan;55(1):16-22
pubmed: 17079159
Clin Pharmacokinet. 2006;45(1):33-58
pubmed: 16430310
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Oct 15;969:117-22
pubmed: 25168795
AAPS J. 2013 Jan;15(1):242-9
pubmed: 23180159
Drug Metab Rev. 2016 May;48(2):266-80
pubmed: 27186889
Biopharm Drug Dispos. 2009 May;30(4):185-203
pubmed: 19544285
Lancet Oncol. 2017 Oct;18(10):1317-1326
pubmed: 28844816
Lancet Oncol. 2015 Sep;16(9):1099-1110
pubmed: 26296954
Cancer Chemother Pharmacol. 2012 Jun;69(6):1457-66
pubmed: 22382880
Rapid Commun Mass Spectrom. 2006;20(7):1117-26
pubmed: 16523529
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:132-141
pubmed: 30754019
Chem Res Toxicol. 2009 Jun;22(6):1194-204
pubmed: 19480391